Merrion Pharm Plc IRSH Novo Nordisk Trial Result

  Merrion Pharm Plc (IRSH) - Novo Nordisk Trial Result

RNS Number : 8550P
Merrion Pharmaceuticals Public Ltd
31 October 2012

  Novo Nordisk A/S Successfully Completes Single Dose Phase 1 Trial of Oral
   GLP-1 Analogue (NN9926) Using Merrion Pharmaceuticals GIPET Technology.

Merrion Pharmaceuticals plc (ESM:MERR), today announces that its partner, Novo
Nordisk, successfully completed a Phase I trial with an oral formulation of  a 
Novo  Nordisk  proprietary  GLP-1  analogue.  Merrion's  proprietary   GIPET 
Technology was incorporated in  the formulation in order  to enhance the  oral 
bioavailability of the drug.

The  aim  of  the  trial  was   to  investigate  the  safety,  tolerance   and 
pharmacokinetics, of the GLP-1 analogue NN9926.

Under the terms of the license agreement signed in January 2009, Merrion  will 
receive payments for  products developed  under the  agreement. Payments  are 
based on achievement of certain  development, regulatory and sales  milestones 
as well  as  royalties. Certain  milestone  payments have  been  received  by 
Merrion as a result of this successful Phase 1 trial.

Merrion's Chairman,  Michael Donnelly  said  "We are  very pleased  with  this 
outcome and the commitment  of Novo Nordisk to  the continuing development  of 
Merrion's GIPET technology in this field".

                     This information is provided by RNS
           The company news service from the London Stock Exchange


MSCBKKDDBBDDOKN -0- Oct/31/2012 09:00 GMT
Press spacebar to pause and continue. Press esc to stop.